Pioneering Public-Private Cancer Initiative
with Unified Leadership Committed to Changing the Course of Cancer
Care
Today, The Abramson Cancer Center at the University of
Pennsylvania, The Herbert Irving Comprehensive Cancer Center at
Columbia University Medical Center, the Sidney Kimmel Comprehensive
Cancer Center at Johns Hopkins, and The Tisch Cancer Institute at
the Icahn School of Medicine at Mount Sinai announced the
establishment of a research consortium focused on accelerating the
discovery and development of novel cancer therapeutics and
diagnostics for the benefit of patients.
The consortium aligns four major academic institutions in a
unified partnership with the shared goal of creating high-impact
research programs to discover new treatments for cancer. The
magnitude of the multi-institutional consortium and agreements
between Celgene Corporation (NASDAQ:CELG) and each institution will
support the rapid delivery of disease-altering programs to the
clinic that may ultimately benefit cancer patients, global
healthcare systems and society.
Subsequent to establishing the consortium, Celgene entered into
four public-private collaboration agreements in which it paid a
total of $50 million, $12.5 million to each institution, for the
option to enter into future agreements to develop and commercialize
novel cancer therapeutics arising from the consortium’s efforts.
Over the next ten years the institutions intend to present multiple
high-impact research programs to Celgene with the goal of
developing new life-saving therapeutics. Subject to Celgene’s
decision to opt-in and license the resulting technologies, each
program has the potential to be valued at hundreds of millions of
dollars.
The four cancer center directors, Steven Burakoff, M.D., of the
Icahn School of Medicine at Mount Sinai, Stephen G. Emerson, M.D.,
Ph.D., of Columbia University, William Nelson, M.D., Ph.D., of
Johns Hopkins University and Chi Van Dang, M.D., Ph.D., of the
University of Pennsylvania, said in a shared statement, “The active
and coordinated engagement, creative thinking and unique
perspectives and expertise of each institution have made this
collaboration a reality. Our shared vision and unified approach to
biomedical research, discovery and development, combined with
Celgene’s vast research, development and global commercial
expertise, will enable us to accelerate the development and
delivery of next-generation cancer therapies to patients
worldwide.”
In addition to the benefits of long-standing professional
relationships among the four cancer center directors, the depth and
breadth of the institutions’ combined research and clinical
infrastructures provide an exceptional foundation upon which to
build this transformative collaboration. The four institutions
collectively care for more than 30,000 new cancer patients each
year, and have nearly 800 faculty members who are active in basic
and clinical research, and clinical care.
“This is a paradigm-shifting collaboration that further
strengthens our innovative ecosystem,” said Bob Hugin, Executive
Chairman of Celgene Corporation. “We remain firmly committed to
driving critical advances in cancer and believe the tremendous
expertise of our collaboration partner institutions will be
invaluable in identifying new therapies for cancer patients.”
The four consortium members are among the 69 institutions
designated as Cancer Centers by the National Cancer Institute
(NCI). These 69 institutions serve as the backbone of NCI’s
research in the war against cancer.
The Cancer Trust, a non-profit organization, brought together
the four institutions, thereby establishing the multi-institutional
research consortium. T.R. Winston & Company, LLC served as the
strategic advisor to The Cancer Trust and facilitated negotiations
among The Cancer Trust, the institutions and Celgene. The
commercialization offices of the four institutions, Columbia
Technology Ventures, Johns Hopkins Technology Ventures, Mount Sinai
Innovation Partners and the Penn Center for Innovation,
subsequently collaborated with Celgene to accelerate this effort to
discover and develop new therapies for the treatment of cancer.
“We are extremely proud of what we’ve collectively accomplished
through establishing this collaboration and aligning all
participants,” said Erik Lium, Ph.D., Senior Vice President of
Mount Sinai Innovation Partners. “We look forward to
continuing to work closely with one another, our colleagues in
research and clinical care, and now with Celgene to advance the
discovery of new therapies that will dramatically improve the lives
of patients worldwide.”
About Celgene Corporation
Celgene Corporation, headquartered in Summit, New Jersey, is an
integrated global biopharmaceutical company engaged primarily in
the discovery, development and commercialization of innovative
therapies for the treatment of cancer and inflammatory diseases
through next-generation solutions in protein homeostasis,
immuno-oncology, epigenetics, immunology and neuro-inflammation.
For more information, please visit www.celgene.com. Follow Celgene
on Social Media: @Celgene, Pinterest, LinkedIn, Facebook and
YouTube.
About The Tisch Cancer Institute at the Icahn School of
Medicine at Mount Sinai
The Tisch Cancer Institute (TCI) is a world-class translational
cancer institute established in December 2007. TCI has recruited
more than 30 acclaimed physicians and researchers specializing in
basic research, clinical research and population science; built
outstanding programs in solid tumor oncology; enhanced existing
robust programs in hematological malignancies; and advanced the
study of cancer immunology and vaccine therapy. The completion of
the Leon and Norma Hess Center for Science and Medicine in 2012
enabled the recruitment of 25 additional cancer researchers on two
full research floors, with 48,000 square feet of space dedicated to
cancer research. In 2015, TCI was named a National Cancer
Institute-designated cancer center. TCI joined an elite group of 69
cancer institutions nationwide that have earned this designation,
which is based on scientific excellence, robust clinical research,
and beneficial community impact. To learn more about clinical
trials at Mount Sinai, visit
http://icahn.mssm.edu/research/clinical-trials.
About the Herbert Irving Comprehensive Cancer Center of
Columbia University Medical Center / New York-Presbyterian
The Herbert Irving Comprehensive Cancer Center (HICCC) of
Columbia University (CU) is the University’s organizational
structure for the conduct of basic, clinical and population-based
cancer research and patient care. Cancer Center researchers and
physicians are dedicated to understanding the biology of cancer and
to applying that knowledge to the design of cancer therapies and
prevention strategies that reduce its incidence and progression and
improve the quality of the lives of those affected by cancer.
Columbia’s interest in cancer research dates from 1911 with the
creation of the Institute for Cancer Research. Initially funded by
the National Cancer Institute (NCI) in 1972 and designated
comprehensive in 1979, the HICCC is one of 45 NCI-designated
comprehensive cancer centers in the United States, of which only
four are in New York State.
Today, the HICCC has more than 200 members from six schools at
Columbia University. Current NCI funding to members is more than
$33 million and Cancer Center members have been awarded over $95
million (total costs) in total peer-reviewed cancer research
grants.
About the Abramson Cancer Center of the University of
Pennsylvania
The Abramson Cancer Center (ACC) of the University of
Pennsylvania is a world leader in cancer research, patient care,
and education. Its preeminent position is reflected in its
continuous designation as a Comprehensive Cancer Center by the
National Cancer Institute (NCI) since 1973, one of 45 such Centers
in the United States, and its longstanding “exceptional” rating by
the NCI. The ACC’s clinical program is comprised of a dedicated,
multi-disciplinary team of physicians, nurse practitioners, nurses,
social workers, physical therapists, nutritionists, and patient
care coordinators. Each year, the Center has more than 90,000
outpatient visits, over 11,800 inpatient discharges, and provides
37,000 chemotherapy treatments and more than 66,000 radiation
treatments to its patients. In addition, the ACC is home to more
than 400 basic, translational, and clinical scientists who work in
tandem to advance new treatments and cures for cancers of all
kinds.
About Johns Hopkins Medicine
Johns Hopkins Medicine (JHM), headquartered in Baltimore,
Maryland, is a $7.7 billion integrated global health enterprise and
one of the leading academic health care systems in the United
States. JHM unites physicians and scientists of the Johns Hopkins
University School of Medicine with the organizations, health
professionals and facilities of The Johns Hopkins Hospital and
Health System. JHM's vision, "Together, we will deliver the promise
of medicine," is supported by its mission to improve the health of
the community and the world by setting the standard of excellence
in medical education, research and clinical care. Diverse and
inclusive, JHM educates medical students, scientists, health care
professionals and the public; conducts biomedical research and
provides patient-centered medicine to prevent, diagnose and treat
human illness. JHM operates six academic and community hospitals,
four suburban health care and surgery centers, and more than 39
primary and specialty care outpatient sites under the umbrella of
Johns Hopkins Community Physicians. JHM extends health care into
the community and globally through Johns Hopkins Home Care Group,
Johns Hopkins Medicine International and Johns Hopkins HealthCare.
The Johns Hopkins Hospital, opened in 1889, has been ranked number
one in the nation by U.S. News & World Report for 22 years of
the survey's 26-year history.
Since its opening in 1973, the Sidney Kimmel Comprehensive
Cancer Center at Johns Hopkins is a world leader in deciphering the
mechanisms of cancer and new ways to treat it. The strength of the
Kimmel Cancer Center's research and treatment programs was
recognized early on by the National Cancer Institute (NCI),
becoming one of the first to earn comprehensive cancer center
status and recognition as a "Center of Excellence." It is one of
only two NCI-affiliated cancer centers designated as
"comprehensive" in the state of Maryland.
For more information about Johns Hopkins Medicine, its research,
education and clinical programs, and for the latest health, science
and research news, visit www.hopkinsmedicine.org.
About The Cancer Trust
The Cancer Trust, (www.cancertrust.org) a 501(c)(3) charitable
organization, focuses on identifying and forming academic and
pharmaceutical industry research collaborations to discover,
develop and commercialize novel cancer diagnostic and therapeutic
products. Its mission is to foster collaborative team science based
on aligning interests and creating shared objectives. The Cancer
Trust grew from a series of "Think Tank" meetings attended by New
York’s financial and cancer care professionals. These meetings were
led by Fighting Chance (www.fightingchance.org), a free cancer
counseling center on Long Island founded by Duncan Darrow in 2002.
The Cancer Trust was established in 2013. In addition to T.R.
Winston & Company having served as the Trust’s strategic
advisor for the collaborations announced today, the Trust’s
advisors also include Booz Allen Hamilton, Sidley Austin LLP,
Morgan Stanley and Spencer Stuart.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160622005377/en/
For more information about Celgene Corporation:Brian Gill,
908-673-9530Vice President, Global Corporate
Communicationsbgill@celgene.comorFor more information about The
Tisch Cancer Institute at the Icahn School of Medicine at Mount
Sinai:Lucia Lee, 212-241-9200Director of
Medialucia.lee@mountsinai.orgorFor more information about the
Herbert Irving Comprehensive Cancer Center:Karin Eskenazi,
212-342-0508Director, Media Relationsket2116@cumc.columbia.eduorFor
more information about the Abramson Cancer Center:Holly Auer,
215-349-5659 or 215-200-2313 (cell)Penn Medicine Communications
Directorholly.auer@uphs.upenn.eduorFor more information about Johns
Hopkins Medicine:Jania Matthews, 410-955-5385Assistant Director of
Public Relations and Corporate Communicationsjmatth27@jhmi.eduorFor
more information about The Cancer Trust:Chamberlain Healthcare
PRSusan Thiele, 212-849-9446Executive Vice
Presidentsusan.theile@inventivehealth.com
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Apr 2024 to May 2024
Celgene (NASDAQ:CELG)
Historical Stock Chart
From May 2023 to May 2024